RCM
KROS icon

RA Capital Management’s Keros Therapeutics KROS Stock Holding History

RA Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,875,000
Closed -$132M – 89
2020
Q4 		$132M Hold
1,875,000
– – 1.85% 12
2020
Q3 		$72.3M Hold
1,875,000
– – 1.32% 26
2020
Q2 		$70.3M Buy
+1,875,000
New +$57.8M 1.37% 25

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RA Capital Management's KROS Position: Q1 2021 in Review

RA Capital Management sold out of Keros Therapeutics (KROS) in Q1 2021, closing a stake of 1,875,000 shares — an estimated $132M sold.

RA Capital Management first reported a position in KROS in Q2 2020 and held it in 3 quarters. The position peaked at $132M in Q4 2020. 83 funds tracked by Wall St. Rank hold KROS as of Q1 2021.

  • RA Capital Management reported no remaining Keros Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RA Capital Management sold 1,875,000 Keros Therapeutics shares in Q1 2021, an estimated $132M.
  • RA Capital Management first reported a position in Keros Therapeutics in Q2 2020 and held it in 3 quarters.
  • RA Capital Management's Keros Therapeutics position peaked at $132M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2021.

Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.